FLT3 and acute myeloid leukemia: To further explore whether AXL is an effective therapeutic target for preventing adaptive resistance in FLT3/ITD AML, we inhibited AXL with two different inhibitors, TP‐0903 or R428, concurrently with FLT3 TKI treatment [45, 46, 47].